Although it has been reported that the presence of anticardiolipin antibodies (aCL) is a strong predictor of worse long-term renal outcome in LN regardless of whether the criteria for an APS diagnosis are met [6, 7], the renoprotective effect of antiplatelet therapy has not been evaluated. The gene discussed is ACLY; the disease is autoimmune polyendocrinopathy.